AttendMe Owl Logo
AttendMe
Sign In
All Pathways
Hematology & OncologyEmergency

Hyperleukocytosis and Leukostasis Management

Hyperleukocytosis and Leukostasis Management: Hyperleukocytosis: WBC >100 × 10^9/L → Emergency: admit and call haematology now → Lab artefacts: do not t...

Pathway Overview

21 steps

Algorithm Steps

21 total

  1. 01Start

    Hyperleukocytosis: WBC >100 × 10^9/L

    Adult with known or suspected leukaemia. Leukostasis can also occur at WBC <100 × 10^9/L.

  2. 02Action

    Emergency: admit and call haematology now

    Adults. Pregnancy test if she could be pregnant. Low threshold for ICU review. Child: call paediatric haematology now; this pathway is for adults.

    • Blood film: look for blasts and APL (promyelocytes, Auer rods)
    • Coagulation: PT, APTT, fibrinogen, D-dimer (DIC is common)
    • TLS bloods: K+, phosphate, calcium, urate, creatinine, LDH
    • G6PD status before rasburicase
  3. 03Warning

    Lab artefacts: do not treat numbers alone

    Very high WBC can give false results. The automated platelet count can be falsely high: check the blood film.

    • Low PaO2 on blood gas can be false (cells use O2 in the sample): trust SpO2
    • High serum K+ can be false: confirm with whole-blood K+ on a blood gas analyser. ECG changes of hyperkalaemia: treat at once
    • Take samples to the lab at once
  4. 04Decision

    Which leukaemia?

    Suspected APL, CLL, or other (AML, ALL, CML)

  5. Suspected APL
  6. 05Warning

    Suspected APL: start ATRA now

    Do not wait for genetic confirmation. Different management. Pregnant: no ATRA in the first trimester; no arsenic trioxide (ATO) at any stage. Haematology and obstetrics decide now.

    • Start ATRA (tretinoin) at first suspicion, with haematology. Adult: 45 mg/m2/day orally in 2 divided doses (renal or hepatic impairment: 25 mg/m2/day)
    • Treat coagulopathy now: fibrinogen >1.0-1.5 g/L, platelets >30-50 × 10^9/L, INR <1.5
    • No leukapheresis (can cause fatal bleeding). Avoid central lines, lumbar puncture, bronchoscopy
  7. 06Action

    APL: high TLS risk: IV fluids and rasburicase (not if G6PD deficient)

    AML (including APL) with WBC ≥100 × 10^9/L is high TLS risk. Start now, before or with cytoreduction. Reduce fluids if oliguria, renal failure, fluid overload or hypoxaemia. Previous reaction to rasburicase: use allopurinol.

    • IV fluids about 3 L/m2/day; watch fluid balance closely
    • Adult: rasburicase 0.2 mg/kg IV over 30 min once daily, up to 7 days (no maximum set in the PI)
    • G6PD deficient, previous rasburicase reaction, or no rasburicase: allopurinol; adjust dose for renal function
    • No potassium in IV fluids. K+, phosphate, calcium, urate, creatinine at least every 6 h
    • After rasburicase: urate sample on ice, analysed within 4 h
  8. 07Action

    APL (WBC >10 × 10^9/L = high risk): haematology care

    Haematology directs induction. Pregnancy: no arsenic trioxide (ATO); no ATRA in the first trimester.

    • Start cytoreductive chemotherapy without delay, even before molecular results
    • Blood products for fibrinogen and platelet targets; coagulation tests at least daily. No routine tranexamic acid or heparin
    • Differentiation syndrome (dyspnoea, fever, weight gain, infiltrates): dexamethasone 10 mg IV twice daily at first suspicion; stop ATRA or ATO only if severe. High WBC: consider prophylactic steroids, per haematology
  9. 08Outcome

    APL: induction under haematology

    Continue APL treatment per haematology.

  10. AML, ALL or CML
  11. 09Action

    AML, ALL or CML: screen for leukostasis

    Leukostasis is a clinical diagnosis. It is more common in AML than ALL.

    • Lungs: dyspnoea, hypoxaemia, diffuse infiltrates
    • Brain: confusion, headache, visual change, stroke, intracranial bleeding
    • Kidney: acute kidney injury
    • Retinal haemorrhage; priapism
  12. 10Decision

    Symptoms of leukostasis?

    Respiratory, neurological or other end-organ signs

  13. If Yes
    1. 11Warning

      Leukostasis present: emergency

      ICU review now. Start cytoreduction without delay.

      • Oxygen and respiratory support as needed
      • Avoid red cell transfusion until WBC falls; if essential, transfuse slowly
      • Treat DIC: platelets, FFP, fibrinogen
    2. 12Action

      High TLS risk: IV fluids and rasburicase (not if G6PD deficient)

      AML or ALL with WBC ≥100 × 10^9/L is high TLS risk. Reduce fluids if oliguria, renal failure, fluid overload or hypoxaemia. Previous reaction to rasburicase: use allopurinol.

      • IV fluids about 3 L/m2/day; watch fluid balance closely
      • Adult: rasburicase 0.2 mg/kg IV over 30 min once daily, up to 7 days (no maximum set in the PI). One dose, repeated if needed, is often enough
      • G6PD deficient, previous rasburicase reaction, or no rasburicase: allopurinol; adjust dose for renal function
      • No potassium in IV fluids
      • K+, phosphate, calcium, urate, creatinine at least every 6 h
      • After rasburicase: urate sample on ice, analysed within 4 h
      • Chronic-phase CML: TLS risk is lower; fluids and allopurinol are usually enough. CML in blast phase: manage as for acute leukaemia
    3. 13Action

      Cytoreduction: start now

      Pregnancy: hydroxyurea can harm the fetus; haematology and obstetrics decide.

      • AML fit for intensive treatment: start induction chemotherapy as soon as the diagnosis is made
      • Hydroxyurea (dose per haematology): if not fit for intensive induction, if induction must wait (for example severe metabolic or renal problems), or as a short bridge if diagnosis is unclear
      • Do not delay induction to wait for WBC to fall
      • ALL: steroid prephase and induction per protocol
      • CML: hydroxyurea until specific therapy starts, per haematology
    4. 14Decision

      Leukapheresis? (not routine; never in APL)

      Consider only for leukostasis with worsening end-organ function, where available, with haematology.

    5. If Yes
      1. 15Action

        Leukostasis, apheresis available: leukapheresis

        Temporary measure. Not in APL. Caution with severe coagulopathy, heart disease or unstable circulation.

        • One session lowers WBC by about 30-60%
        • Continue cytoreduction and induction
        • No proven benefit on early death or survival
        • Repeat per apheresis team if symptoms persist
      2. 16Action

        Supportive care and monitoring

        Frequent reassessment in HDU or ICU.

        • Electrolytes and urate at least every 6 h
        • Established TLS (rising K+, phosphate or creatinine, or oliguria): treat hyperkalaemia now; call the renal team early for dialysis
        • Platelets: keep >20-30 × 10^9/L; about 50 × 10^9/L if on full heparin. Bleeding or CNS bleed: higher target per haematology
        • FBC and coagulation at least daily, more often if DIC or bleeding
        • Continuous SpO2 and neurological checks
        • Worse breathing despite falling WBC: look for pneumonia or drug lung injury
      3. 17Outcome

        Leukostasis risk controlled

        Continue definitive leukaemia treatment.

      If No
      1. 18Action

        No leukapheresis: medical management

        Continue cytoreduction, induction and supportive care.

      2. Path rejoins step 16Shared downstream outcome
    If No
    1. 19Action

      No leukostasis: prevent complications

      High risk of leukostasis, TLS and DIC. Admit and monitor closely.

      • Start TLS prophylaxis and cytoreduction now
      • Avoid red cell transfusion unless symptomatic anaemia
    2. Path rejoins step 12Shared downstream outcome
  14. CLL
  15. 20Action

    CLL: leukostasis is rare

    High count alone seldom needs emergency cytoreduction.

    • Look for other causes of symptoms (infection, transformation)
    • Pseudohyperkalaemia is common in CLL: confirm K+ before treatment
    • If leukostasis symptoms: urgent haematology decision on cytoreduction or leukapheresis
    • Treat the CLL per haematology
  16. 21Outcome

    CLL: haematology-directed care

    Treat underlying CLL per haematology.

Guideline Source

How I treat hyperleukocytosis in acute myeloid leukemia (Röllig & Ehninger, Blood 2015)

DOI: 10.1182/blood-2014-10-551507View Guideline

Clinical Safety Information

Clinical Decision Support — Not a Substitute for Clinical Judgment

Individual patient factors may require deviation from these recommendations.

Known Limitations

  • Suspected APL needs ATRA at once and no leukapheresis; see the APL step
  • Hydroxyurea dose is not given; use haematology or local protocol (eviQ)
  • WBC count alone does not predict leukostasis; cell type matters (AML > ALL > CLL)
  • Leukapheresis has no proven benefit on early death; its use depends on the centre
  • Adult pathway; children need paediatric haematology protocols

Contraindicated Populations

Children (use paediatric haematology protocols)Pregnancy (specialist haematology and obstetric decision before cytotoxic drugs)

Applicable Regions

AUUSEUGlobal

AU: Hydroxycarbamide (Hydrea) is TGA-registered for CML, not for AML cytoreduction (off-label use). Rasburicase (Fasturtec) is TGA-registered: 0.2 mg/kg/day IV. Follow eviQ or local haematology protocols.

US: Leukapheresis availability varies by centre

Global: Hydroxyurea is widely available

Version 2Next review: 2027-09-30

Related Hematology & Oncology Pathways

Acute Transfusion Reaction Management

Emergency

Anticoagulant Reversal for Major Bleeding (Warfarin, DOAC, Heparin)

Emergency

Chemotherapy Extravasation Management

Emergency

Disseminated Intravascular Coagulation (ISTH 2025)

Diagnostic

Next steps

Finish the workflow by opening the most relevant calculator, then convert the session into a live account when you are ready.

Calculator

Absolute Neutrophil Count (ANC)

Absolute neutrophil count from CBC for neutropenia grading

Open page

Compare

AttendMe.ai vs OpenEvidence

See how this pathway workflow compares against OpenEvidence.

Open page

Commercial

Start free

Run the pathway in a live AttendMe account with citations and tracked usage.

Start free

Related Resources

All Clinical PathwaysClinical CalculatorsAI Chat with Auto-Detection

Frequently Asked Questions

What is the Hyperleukocytosis and Leukostasis Management?

The Hyperleukocytosis and Leukostasis Management is a emergency clinical algorithm for Hematology & Oncology. It provides a structured decision tree to guide clinical decision-making, based on How I treat hyperleukocytosis in acute myeloid leukemia (Röllig & Ehninger, Blood 2015).

What guideline is the Hyperleukocytosis and Leukostasis Management based on?

This algorithm is based on How I treat hyperleukocytosis in acute myeloid leukemia (Röllig & Ehninger, Blood 2015) (DOI: 10.1182/blood-2014-10-551507).

What are the limitations of the Hyperleukocytosis and Leukostasis Management?

Known limitations include: Suspected APL needs ATRA at once and no leukapheresis; see the APL step; Hydroxyurea dose is not given; use haematology or local protocol (eviQ); WBC count alone does not predict leukostasis; cell type matters (AML > ALL > CLL); Leukapheresis has no proven benefit on early death; its use depends on the centre; Adult pathway; children need paediatric haematology protocols. Individual patient factors may require deviation from these recommendations.

Get AI-Powered Analysis Alongside This Algorithm

In AttendMe.ai, the Hyperleukocytosis and Leukostasis Management appears automatically when your clinical question matches — alongside evidence from 3M+ peer-reviewed articles.

Try AttendMe Free